Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06369155 · ClinicalTrials.gov registry record · Phase 2
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
A Phase 2 study of Uterine Cancer and Uterine Serous Carcinoma, sponsored by Joyce Liu, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 2
- Study locations
NCT06369155 is a Phase 2 study of Uterine Cancer and Uterine Serous Carcinoma that is actively recruiting participants, run by Joyce Liu, MD. The registered enrollment target is 25 participants, below the 270-participant average among 27 other Uterine Cancer trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06369155, a Phase 2 study of Uterine Cancer and Uterine Serous Carcinoma, is actively recruiting participants, sponsored by Joyce Liu, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is being done to investigate how Azenosertib affects tumor cells of persistent or recurrent uterine serous carcinoma. The name of the study drug involved in this study is: -Azenosertib (a type of Wee1 inhibitor)
Conditions Studied
Interventions
- DRUG Azenosertib
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-03-05 |
| Est. Completion | 2028-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06369155
The ClinicalTrials.gov registry entry for NCT06369155 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 270-participant average among 27 other Uterine Cancer trials with a reported enrollment target (91% lower). The listed sponsor is Joyce Liu, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Uterine Cancer appearing as the primary indexed condition, and to 1 intervention - of which Azenosertib is the first listed.
NCT06369155 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06369155 about?
NCT06369155 is a clinical study titled "Azenosertib in Uterine Serous Carcinoma: Biomarker Study". This research study is being done to investigate how Azenosertib affects tumor cells of persistent or recurrent uterine serous carcinoma. The name of the study drug involved in this study is: -Azenosertib (a type of Wee1 inhibitor)
What is the current status of trial NCT06369155?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2025-03-05. Estimated completion is 2028-01-31.
What conditions does trial NCT06369155 study?
This clinical trial studies the following conditions: Uterine Cancer, Uterine Serous Carcinoma, Uterine Carcinoma.
What interventions are being tested in trial NCT06369155?
The interventions under investigation include: Azenosertib (DRUG).
Who is sponsoring clinical trial NCT06369155?
This trial is sponsored by Joyce Liu, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06369155 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uterine Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
RECRUITING · Phase 2
-
[18F]FES PET/.CT in Uterine Cancer
RECRUITING · Phase 2
-
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
RECRUITING · Phase 2
-
AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Nivolumab in Selected Uterine Cancer Patients
COMPLETED · Phase 2
-
Image-Guided Gynecologic Brachytherapy
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.